Get started
Author

Josep Fortea

Observed names: J Fortea, J. Fortea
ORCID: 0000-0002-6368-4214
Observed ORCID: 0000-0002-6368-4214
OpenAlex ID: A5112685857
Early vs. Non-Early Intervention in Acute Migraine — ‘Act When Mild (AwM)’. A Double-Blind, Placebo-Controlled Trial of Almotriptan
2008 · PJ Goadsby, G Zanchin, et al. · Cephalalgia · 219
Randomised clinical trials: linaclotide phase 3 studies in IBS ‐C – a prespecified further analysis based on European Medicines Agency‐specified endpoints
2012 · E. M. M. Quigley, J. Tack, et al. · Alimentary Pharmacology & Therapeutics · 127
Irritable bowel syndrome with constipation: a European-focused systematic literature review of disease burden
2012 · J. Fortea, M. Prior · Journal of Medical Economics · 32
PDF
The efficacy and safety of aceclofenac versus placebo and naproxen in women with primary dysmenorrhoea
2006 · Heinz Letzel, Yves Mégard, et al. · European Journal of Obstetrics & Gynecology and Reproductive Biology · 26
An exploration of the barriers to the confident diagnosis of irritable bowel syndrome: A survey among general practitioners, gastroenterologists and experts in five European countries
2014 · Viola Andresen, Peter Whorwell, et al. · United European Gastroenterology Journal · 25
PDF
The Impact of Allodynia on the Efficacy of Almotriptan When Given Early in Migraine: Data From the “Act When Mild” Study
2011 · S. Díaz-Insa, P. J. Goadsby, et al. · International Journal of Neuroscience · 23
Ebastine fast-dissolving tablets versus regular tablets: acceptability and preference in patients with allergic rhinitis
2008 · A Roger, J Fortea, et al. · Expert Review of Clinical Pharmacology · 15
Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom
2007 · Anna Raber, Joan Heras, et al. · Therapeutics and Clinical Risk Management · 13
PDF
Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg): A randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adults
2007 · Rosa Antonijoan, Consuelo García-Gea, et al. · Clinical Therapeutics · 10
Patient assessment of onset of action and overall satisfaction with ebastine fast-dissolving tablets in allergic rhinitis
2008 · Albert Roger, Josep Fortea, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 9
A Comparison of Ebastine 10mg Fast-Dissolving Tablet with Oral Desloratadine and Placebo in Inhibiting the Cutaneous Reaction to??Histamine in Healthy Adults
2007 · Rosa M Antonijoan, Consuelo Garc??a-Gea, et al. · Clinical Drug Investigation · 8
Economic Burden and Quality of Life of Moderate-To-Severe Irritable Bowel Syndrome With Constipation (Ibs-C) In Germany: Results From The Ibis-C Study
2015 · P Layer, V Andresen, et al. · Value in Health · 5
PDF
The Burden of Moderate-To-Severe Irritable Bowel Syndrome With Constipation (Ibs-C) In France: A Comparison With The European Results From The Ibis-C Observational Study
2015 · B Coffin, M Follet, et al. · Value in Health · 4
OC-066 Economic and quality-of-life burden of moderate-to-severe irritable bowel syndrome with constipation (ibs-c) in the uk: the ibis-c study
2015 · Y Yiannakou, M Eugenicos, et al. · Gut · 4
Economic And Quality-Of-Life Burden Of Moderate-To-Severe Irritable Bowel Syndrome With Constipation (Ibs-C) In Spain: The Ibis-C Study
2014 · F. Mearin, X. Cortes, et al. · Value in Health · 4
Assessment of patient satisfaction with ebastine fast-dissolving tablets in patients suffering from allergic rhinitis
2009 · Albert Roger, Josep Fortea, et al. · Therapy · 3
Pal2 Attributes for Preference of New Fast Dissolving Tablet (fdt) Formulation of Ebastine in Patients With Allergy
2005 · A Roger, J Fortea, et al. · Value in Health · 3
Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Letter]
2019 · Leticia Orsatti, Josep Fortea, et al. · Drug Design Development and Therapy · 1
PDF
Health Care Cost Associated To Constipation Predominant Irritable Bowel Syndrome In Spain
2014 · A. Raya, C. Barrull, et al. · Value in Health · 1
PGI26 Within-Trial Analysis to Estimate the Economically Justifiable Price of Linaclotide in the Treatment of Irritable Bowel Syndrome With Constipation in the UK
2012 · A. McDonell, V. Barzey, et al. · Value in Health · 1
PDF
OC-082 26-Week efficacy and safety of once-daily oral linaclotide in patients with irritable bowel syndrome with constipation (IBS-C): a European perspective
2012 · A J Lembo, J Fortea, et al. · Gut · 1
PDF
[Salmonella virchow meningitis in an infant].
1995 · A Gené, A Rueda, et al. · PubMed · 1
Newborn sepsis caused by Streptococcus pneumoniae.
1992 · C Muñoz, J Fortea, et al. · PubMed · 1
Diagnosis And Management of Moderate-To-Severe Irritable Bowel Syndrome With Constipation (Ibs-C) In Germany: Results From The Ibis-C Study
2015 · P Layer, V Andresen, et al. · Value in Health
PDF
PTU-187 Sample size calculation in confirmatory trials in irritable bowel syndrome with constipation: experience with linaclotide (constella®)
2015 · M Falques, C Díaz, et al. · Gut
Works count: 35
Citation count: 536
H-index: 9
I10-index: 9
Year
Topic
Type